NEWS

By: Dan Leonard, Executive Director, We Work For Health Any driver knows the feeling of being passed on a highway. Sometimes, you see the other car coming from a mile away; you might even change lanes to ease the overtake. Other times, a fellow commuter with a heavy foot emerges from seemingly nowhere, buzzing past audibly at an incredible speed. China’s biopharmaceutical industry, souped up with state funding, a history of intellectual property appropriation, and an aggressi

A guest perspective by: Henry Hadad, Senior Vice President, Innovation Law, Bristol Myers Squibb Over the past century, the biopharmaceutical industry has delivered extraordinary advances that have fundamentally transformed human health. Immuno-oncology has extended survival for patients with metastatic melanoma from eight months in the 1990s to six years today. Antiretrovirals allow HIV patients to live normal lives. Antibiotics have slashed mortality from infectious disease

By: Dan Leonard, Executive Director, We Work For Health and Chrissy Buteas, President and Chief Executive Officer, HealthCare Institute of New Jersey Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricin

By: Dan Leonard, Executive Director, We Work For Health Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives. Last year marked a transformative moment for the biopharmaceutical sector: the industry committed to nearly $500 billion in domestic investments, an almost 1,500% surge compared to 2024. My organization, We Work For Health, documents where these investments flow on our U.S. Biopharma Investment Wa

By: Richard Bagger, Board Member, Center for Medicine in the Public Interest; former New Jersey State Legislator and Chief of Staff to New Jersey Governor Chris Christie. When government officials propose policies that set prices for life-saving medicines, the idea can sound simple: make prescription drugs more affordable and easier to access. But history, economics, and global experience tell a much different story. Government price controls, including importing other count

By: Debbie Hart, CEO, BioNJ and Dan Leonard, Executive Director, We Work For Health Will the epicenter of global medical innovation be in New Jersey or Shanghai? That is a critical question before U.S. policymakers right now, and the stakes arguably couldn’t be higher. How the country fends off China’s rising biopharma sector affects everything from our health and national security to local, state and national economies. Today, the U.S. leads the world in biopharmaceutical in

By: Dan Leonard, Executive Director, We Work For Health The decades-long partnership between the federal government, research-focused...

By: Dan Leonard, Executive Director, We Work For Health Kansas is both a driver and a beneficiary of the most sustained period of growth...

By: Tom Kowalski, Co-Chair, We Work For Health Recent efforts to revive the so-called “Most Favored Nation” (MFN) drug pricing policy...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health What do North Carolina’s incredible universities have in common, in...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health Smart policymaking and American ingenuity have combined to create an...

While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...

The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...

Forty-three years ago, a young U.S. Sen. Joe Biden voted for a transformative policy reform that subsequently catalyzed upwards of $2...

The idea that the government could forcibly seize ownership of a groundbreaking invention you created is chilling. But that is the...

The Biden administration may soon gut the Bayh-Dole Act, one of our nation's most important and impactful laws that also supports nearly...

The inflationary spiral that drove prices up during the first years of the Biden administration has ended. That’s the good news. The bad...

Investment in U.S. biotechnology could be about to plummet, with major implications for future innovation. It all depends on the outcome...

The Biden administration is out to break the law. It’s proposed a framework for federal agencies to impose “march-in” rights on patented...